Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis

Trial Profile

Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Sargramostim (Primary)
  • Indications Pulmonary alveolar proteinosis
  • Focus Adverse reactions
  • Acronyms PharmPAP
  • Most Recent Events

    • 11 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Mar 2018.
    • 11 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 31 Jul 2017 Planned initiation date changed from 15 Jul 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top